Compare Nuvalent Inc (NUVL) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs Twist Bioscience Corp — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Nuvalent Inc is the larger of the two by market cap, and Nuvalent Inc is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals.
| NUVL | TWST | |
|---|---|---|
Market Cap | $9.81B | $5.45B |
Sector | Technology | Health |
52-Week High | $123.96 | $102.88 |
52-Week Low | $72.16 | $24.16 |
Enterprise Value | $8.52B | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
